Results 131 to 140 of about 95,860 (291)

Fatal Pembrolizumab‐Induced Stevens‐Johnson Syndrome/Toxic Epidermal Necrolysis in a Patient With Advanced Lung Adenocarcinoma

The Kaohsiung Journal of Medical Sciences, EarlyView.
Po‐Chih Chang, Ting‐Wei Chang, Chia‐Yu Kuo, Yi‐Zhe Wu   +3 more
wiley   +1 more source

Harnessing Natural Compounds in Psoriasis: Targeting Cellular Pathways for Effective Therapy

Phytotherapy Research, EarlyView.
Natural compounds act on key cellular pathways in psoriasis by suppressing keratinocyte hyperproliferation, modulating Th17/IL‐17‐mediated immune responses, and reducing oxidative stress. These multi‐target effects highlight their potential as safer adjunctive therapies alongside conventional treatments.
Hye Jin Lee, Yu Jin So, Il‐Joo Jo, Ji Yong Jang, Tae Han Yook, Jun Ho Lee, Sung Wook Kim, Kangwook Lee, Soo Jung Park, Gabsik Yang   +9 more
wiley   +1 more source

Successful Treatment of Oxaliplatin-Induced Immune Thrombocytopenia in a Schizophrenic Patient With Contraindication to Steroids Using Cyclosporine Plus Eltrombopag: A Case Report. [PDF]

Case Rep Med
Zheng J, Zhou N, Pang D, Zhou S, Zheng H.   +4 more
europepmc   +1 more source

Cyclosporine A ameliorates ulcerative colitis by inhibiting cellular senescence, modulating the JAK2-STAT3/NF-κB signaling pathway, and regulating the gut microbiota-metabolite axis

Bingxiang Zhao, Yingjie Xu, Fuxing Li, Shujia Song, Zhenlin Liu, Jiayu Liu, Zhengze Liu, X. Peter Chen, xiao bo Wang, Hui Zhou, Linlin Zhao   +10 more
openalex   +1 more source

Refractory Lichen Amyloidosis Coexisting With Atopic Dermatitis Responsive to Sequential Janus Kinase Inhibitor Therapy: Upadacitinib Followed by Abrocitinib

The Kaohsiung Journal of Medical Sciences, EarlyView.
Yu‐Ting Tsai, Jui Lan, Shang‐Hung Lin   +2 more
wiley   +1 more source

Machine learning mortality prediction model for cyclosporine therapy in pediatric aplastic anemia. [PDF]

Ann Hematol
Wen X, Xiao L, Li D, Liao M, Liu Y, Liu Q, Guan X, Dou Y, Hua Z.   +8 more
europepmc   +1 more source

Clinical Characteristics and Risk Factors for Cutaneous Manifestations Associated With Nemolizumab in Atopic Dermatitis: A Multicenter Retrospective Study in Japan

The Journal of Dermatology, EarlyView.
ABSTRACT Nemolizumab, an anti‐interleukin‐31 receptor A monoclonal antibody, has been approved in Japan for treating atopic dermatitis (AD)‐associated pruritus. While it is effective for itch control, nemolizumab‐associated cutaneous adverse events have been increasingly recognized, yet their clinical features remain poorly characterized. In this study,
Wataru Sasaki, Ryo Saito, Kenta Suzuki, Daisuke Watanabe, Masako Minami‐Hori, Hirofumi Kamada, Hiroo Amano, Akihiko Uchiyama, Sei‐ichiro Motegi, Machiko Kamura, Kazunari Sugita, Noriko Kubota, Toshifumi Nomura, Maki Ozawa, Toshiya Takahashi, Takashi Yamakita, Kazumitsu Sugiura, Tetsuharu Ikegami, Ken Igawa, Yuka Kimura, Yoko Kataoka, Ryoichi Kamide, Masakazu Takahashi, Akio Tanaka, Mariko Sugawara‐Mikami   +24 more
wiley   +1 more source

The Role of Cyclosporine in the Treatment of Severe Ulcerative Colitis in the Pediatric Population: A Narrative Review Exploring Known Strategies and New Possibilities. [PDF]

J Clin Med
Dancewicz A, Akutko K, Szyller HP, Augustynowicz G, Pytrus T.   +4 more
europepmc   +1 more source

Treatment Satisfaction, Efficacy, and Safety of Delgocitinib Ointment Following Switch From Topical Corticosteroids for Trunk and Extremity Rash in Atopic Dermatitis

The Journal of Dermatology, EarlyView.
ABSTRACT Atopic dermatitis (AD) is a chronic inflammatory disease characterized by recurrent remissions and relapses. Topical anti‐inflammatory steroids are commonly used for treatment, but their long‐term use poses concerns because of potential side effects. Delgocitinib ointment, a Janus kinase inhibitor, has demonstrated efficacy in several clinical
Masatoshi Abe, Atsuyuki Igarashi, Hiroyuki Kitajima, Hiroyuki Toyama, Kenji Kabashima, Hidehisa Saeki   +5 more
wiley   +1 more source

The Effect of Chronic Graft-Versus-Host Disease and Its Therapy on Salivary Caries Risk Factors-An Exploratory Cross-Sectional Pilot Study. [PDF]

Healthcare (Basel)
Vovk N, Urek M, Cankar K, Nemeth L.
europepmc   +1 more source